Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV Medicine
- PMID: 10985307
- DOI: 10.1097/00002030-200008180-00005
Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV Medicine
Abstract
Objective: To describe the short-term changes in CD4 lymphocyte counts after the interruption of antiretroviral HIV therapy in order to increase the understanding of CD4 lymphocyte dynamics, and so that appropriate monitoring strategies can be designed.
Methods: We studied 35 HIV-infected patients with late-stage disease who had therapy interruptions leading to high viral load levels, median greater than 750 000 RNA log10 copies/ml, and in whom two CD4 cell counts (median 28 days apart) were available before beginning a salvage regimen.
Results: Overall, there was a substantial decline in CD4 cell counts from a median of 125 to 83 cells/mm3 in the average 28 day period, with median proportionate and absolute losses of 26% and 24 cells/mm3 per month, respectively (P < 0.008). This tended to be greater in individuals studied sooner after interrupting therapy (P = 0.03) and in those with CD4 cell counts above the pre-therapy baseline (P = 0.06). There was a strong negative correlation between the proportionate increase in viral load and the absolute change in CD4 cell count (-0.66, P = 0.0002).
Conclusion: Patients with relatively advanced HIV infection interrupting antiretroviral therapy after failing a protease inhibitor-containing regimen require frequent monitoring because CD4 cell counts appear to fall quite rapidly, at least in the first few weeks after interruption.
Similar articles
-
HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.AIDS. 1999 Apr 16;13(6):F35-43. doi: 10.1097/00002030-199904160-00001. AIDS. 1999. PMID: 10397555
-
Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.AIDS. 1999 May 28;13(8):951-6. doi: 10.1097/00002030-199905280-00011. AIDS. 1999. PMID: 10371176
-
Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.AIDS. 1998 Jul 30;12(11):1333-40. doi: 10.1097/00002030-199811000-00015. AIDS. 1998. PMID: 9708413
-
Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.AIDS. 1999 Sep;13 Suppl 1:S49-59. AIDS. 1999. PMID: 10546785 Review.
-
Antiretroviral therapy for patients with HIV disease.Br J Clin Pharmacol. 1998 Mar;45(3):221-8. doi: 10.1046/j.1365-2125.1998.00673.x. Br J Clin Pharmacol. 1998. PMID: 9517365 Free PMC article. Review. No abstract available.
Cited by
-
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD006148. doi: 10.1002/14651858.CD006148. Cochrane Database Syst Rev. 2006. PMID: 16856117 Free PMC article.
-
Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.HIV Med. 2015 Feb;16(2):76-87. doi: 10.1111/hiv.12173. Epub 2014 Sep 1. HIV Med. 2015. PMID: 25174373 Free PMC article.
-
HIV-specific cellular immune responses are stimulated by structured treatment interruption in chronically HIV-1 infected Koreans.Yonsei Med J. 2006 Apr 30;47(2):282-6. doi: 10.3349/ymj.2006.47.2.282. Yonsei Med J. 2006. PMID: 16642563 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials